Blood group A enhances SARS-CoV-2 infection.
| Title: | Blood group A enhances SARS-CoV-2 infection. |
|---|---|
| Authors: | Wu SC; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Arthur CM; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Jan HM; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Garcia-Beltran WF; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA.; Patel KR; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Rathgeber MF; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Verkerke HP; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.; Cheedarla N; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.; Jajosky RP; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Paul A; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Neish AS; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.; Roback JD; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.; Center for Transfusion Medicine and Cellular Therapies, Emory University School of Medicine, Atlanta, GA.; Josephson CD; Department of Hematology and Oncology, Johns Hopkins University All Children's Hospital, St. Petersburg, FL.; Wesemann DR; Division of Allergy and Clinical Immunology and Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Kalman D; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.; Rakoff-Nahoum S; Division of Infectious Disease, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA.; Cummings RD; National Center for Functional Glycomics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.; Stowell SR; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. |
| Source: | Blood [Blood] 2023 Aug 24; Vol. 142 (8), pp. 742-747. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2021- : [New York] : Elsevier; Original Publication: New York, Grune & Stratton [etc.] |
| MeSH Terms: | COVID-19*; Humans ; SARS-CoV-2 ; ABO Blood-Group System ; Galectins |
| Abstract: | Among the risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ABO(H) blood group antigens are among the most recognized predictors of infection. However, the mechanisms by which ABO(H) antigens influence susceptibility to COVID-19 remain incompletely understood. The receptor-binding domain (RBD) of SARS-CoV-2, which facilitates host cell engagement, bears significant similarity to galectins, an ancient family of carbohydrate-binding proteins. Because ABO(H) blood group antigens are carbohydrates, we compared the glycan-binding specificity of SARS-CoV-2 RBD with that of galectins. Similar to the binding profile of several galectins, the RBDs of SARS-CoV-2, including Delta and Omicron variants, exhibited specificity for blood group A. Not only did each RBD recognize blood group A in a glycan array format, but each SARS-CoV-2 virus also displayed a preferential ability to infect blood group A-expressing cells. Preincubation of blood group A cells with a blood group-binding galectin specifically inhibited the blood group A enhancement of SARS-CoV-2 infection, whereas similar incubation with a galectin that does not recognize blood group antigens failed to impact SARS-CoV-2 infection. These results demonstrated that SARS-CoV-2 can engage blood group A, providing a direct link between ABO(H) blood group expression and SARS-CoV-2 infection.; (© 2023 by The American Society of Hematology.) |
| Grant Information: | R01 AI171100 United States AI NIAID NIH HHS; R01 HL135575 United States HL NHLBI NIH HHS; R01 HL165975 United States HL NHLBI NIH HHS; T32 HL066987 United States HL NHLBI NIH HHS |
| Substance Nomenclature: | 0 (ABO Blood-Group System); 0 (Galectins) |
| SCR Organism: | SARS-CoV-2 variants |
| Entry Date(s): | Date Created: 20230627 Date Completed: 20230825 Latest Revision: 20240516 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10294591 |
| DOI: | 10.1182/blood.2022018903 |
| PMID: | 37367252 |
| Database: | MEDLINE |
Journal Article; Research Support, N.I.H., Extramural